Affymax Inc.'s (Nasdaq: AFFY) anemia treatment Hematide met the goals of four Phase 3 studies but a higher incidence of cardiovascular events among a subgroup of patients raised safety issues. The stock price plummeted $15.83 to close at $7.18.
Safety Issues Raised About Affymax's Anemia Drug
June 21, 2010 at 17:08 PM EDT
